BMS Caffeine Adjuvancy Study Acetaminophen-Only Arm Unnecessary – FDA
This article was originally published in The Tan Sheet
Executive Summary
An acetaminophen-only treatment arm in Bristol-Myers Squibb's planned clinical study on the efficacy of different caffeine doses in analgesic adjuvancy is unnecessary, FDA says in a recent letter